Graham-Little syndrome

B. Zegarska, D. Kallas, R. A. Schwartz, R. Czajkowski, G. Uchanska, and W. Placek

Graham-Little syndrome, also known as Graham-Little-Piccardi-Lassueur syndrome, is an unusual form of lichen planopilaris, characterized by the presence of cicatricial alopecia on the scalp, keratosis pilaris of the trunk and extremities, and non-cicatricial hair loss of the pubis and axillae. We present the case of a 47-year-old woman whose condition was unusual in that there was a prominence of scalp findings. Her treatment included a topical steroid plus systemic prednisone beginning at 30 mg every morning, which rendered her skin smooth, but did not alter her scalp lopecia.

KEYWORDS
lichen planus, lichen planopilaris, alopecia, keratosis pilaris, lichenoid dermatosis, Graham-Little syndrome, Graham-Little-Piccardi-Lassueur syndrome

ABSTRACT
Graham-Little syndrome, also known as Graham-Little-Piccardi-Lassueur syndrome, is an unusual form of lichen planopilaris, characterized by the presence of cicatricial alopecia on the scalp, keratosis pilaris of the trunk and extremities, and non-cicatricial hair loss of the pubis and axillae. We present the case of a 47-year-old woman whose condition was unusual in that there was a prominence of scalp findings. Her treatment included a topical steroid plus systemic prednisone beginning at 30 mg every morning, which rendered her skin smooth, but did not alter her scalp lopecia.

Introduction
Graham-Little syndrome (GLS) was described in 1914 by Piccardi (1) in a patient with progressive cicatricial alopecia of the scalp, non-cicatricial alopecia of the axillae and groin, and follicular lichen planus (LP) on the trunk and extremities, to which he gave the name cheratosi spinulosa (keratotic spinulosa). In 1915, Ernst Graham-Little (2) (1867–1950) published a similar case study that had been referred by Lasseur of Lausanne. GLS is an unusual type of lichen planus called lichen planopilaris that affects the hair follicles (3–10). This rare lichenoid dermatosis is characterized by scarring alopecia, the loss of pubic and axillary hairs, and the progressive development of spinous or accuminate follicular papules on the trunk and extremities. GLS predominantly affects women, the duration of the illness varies from 6 months to 10 years. We present the case of a 47-year-old woman with GLS.

Case report
A 47-year-old woman was referred for evaluation of scalp alopecia and a perifollicular eruption on her trunk and extremities. The illness had begun to present three years prior. Its onset was noted on the skin near the wrists. After about three weeks the papules had intensified and spread to the trunk, including the lumbosacral area and mammary folds, as well as to the lower extremities, especially the thighs. Two to three months after onset, the patient observed gradual hair loss, resulting later in the alopecia foci. Her skin changes were accompanied by a marked and intensified cutaneous pruritus. Her past medical history was non-contributory. There was no family history of a similar eruption.
Upon examination, 2 to 3 mm discrete red-brown follicular keratotic papules were observed on the lumbo-sacral and thigh skin and in mammary folds (Fig 1). On the right occipital scalp and forehead, visible foci devoid of hair were noted, separated from the surrounding scalp and reminiscent of alopecia areata. The remaining hair-bearing skin showed hair thinning and discrete, tiny keratotic papules within the follicular orifices. A similar pattern was also evident on the rim of the hairless scalp foci (Fig 2).

Her laboratory tests were within normal limits, including a complete blood-cell count with differential, routine chemistries, liver and thyroid function tests, serum testosterone and DHEA, chest X-ray, and serum antinuclear antibodies. Skin biopsy specimens from the truncal skin showed hyperkeratosis, acanthosis, and marked vacuolar degeneration of the basal layer with a lichenoid polymorphous infiltrate of predominately lymphocytes sharply demarcated and overlying the follicular orifices (Fig 3). The interfollicular epithelium was spared. Skin biopsy specimens from the scalp revealed hyperkeratosis, acanthosis, granular layer hypertrophy, and vacuolar degeneration of the basal layer overlying both the follicular orifices.
and the interfollicular epithelium (Fig 4). A lichenoid infiltrate, predominately of the lymphocytes, was adherent to both the epidermis and hair follicles. Treatment included the administration of prednisone in a dose of 30 mg each morning, which was decreased after approximately two weeks to 20 mg. Preparations containing corticosteroids were applied locally. After the reduction of oral prednisone, photochemotherapy (PUVA) was used and was continued as outpatient treatment up to a total dosage of 12 Joules.

**Discussion**

Graham-Little syndrome is characterized by the triad of multifocal cicatricial alopecia of the scalp, non-scarring alopecia of the axillae and/or groin, and keratotic follicular papules. In 1915, Graham-Little (2) described a patient's condition using the name keratotic follicular papules. In 1914 by Piccardi (1). Throughout the decades since, this syndrome has caused a lot of controversy (3–6). In 1953, Silver et al. (7) lumped together patients described as having lichen planopilaris, lichen planus, lichen planus acuminatus et atrophicans or lichen spinulosus, and folliculitis decalvans of Graham-Little as having the same condition (8, 9). A study of the clinical, histological, and immunofluorescent findings has likewise shown that it was a type of lichen planus. A similarly affected patient had been reported in 1914 by Piccardi (1). Throughout the decades since, this syndrome has caused a lot of controversy (3–6). In 1953, Silver et al. (7) lumped together patients described as having lichen planopilaris, lichen planus, lichen planus acuminatus et atrophicans or lichen spinulosus, and folliculitis decalvans of Graham-Little as having the same condition (8, 9). A study of the clinical, histological, and immunofluorescent findings has likewise shown the above to all be types of lichen planus (3, 4). Postmenopausal frontal fibrosing alopecia may represent a newly described frontal variant of lichen planopilaris (10, 11), because it can have the same characteristic non-scarring alopecia of the eyebrows and axillae and the facial follicular papules of GLS (12).

The pathogenic mechanisms of GLS remain unexplained (4, 8–16). The illness's main target is the upper half of the pilosebaceous unit, where lymphohistiocytic infiltration begins and is associated with basal cell destruction. The follicles and sebaceous glands are gradually damaged by inflammatory infiltrates and are replaced by connective tissue, this change being represented by scarring. Damage to the follicles may be caused by pressure from the perifollicular infiltrations from one side and the keratinous plugs from the other. Follicular pressure may lead to reduced blood supply and gradual atrophy. A recent report describes an autoimmune response against the INCENP centromere protein in one patient. The significance of this case remains uncertain (17).

GLS is treated topically or by systemic corticosteroids, retinoids, or PUVA therapy, each credited as having partial and temporary benefits (9, 12–17). Another effective treatment is the oral administration of prednisone in doses of 0.5 to 1.0 mg/kg body mass every morning with a simultaneous local application of corticosteroids and PUVA. Our patient was initially treated with 30 mg of prednisone each morning, which was later decreased to 20 mg. The only improvement noted was the gradual disappearance of lichenoid papules on the trunk and extremities. They resolved with only residual discoloration. This effect was especially prominent after the combination of prednisone therapy and PUVA.

In the case of a different patient, cyclosporin A was employed at a dosage of 4 mg/kg/day and produced a substantial reduction of both perifollicular erythema and follicular hyperkeratotic papules (13). After 3 months of follow-up, some areas showed signs of hair re-growth in the scarring patches and a more consistent improvement of the follicular papules were noted. We agree that cyclosporin A can be an effective treatment during the initial phases of this rare variant of lichen planopilaris, before the development of severe follicle damage has taken place, either by interfering with the acute inflammatory processes or by limiting the progression of the disease.

The issue of alopecia merits considerable attention (3, 4, 8, 9, 18–21). It can be challenging to distinguish lichen planopilaris from discoid lupus erythematosus, pseudopelade of Brocq, syphilis, and central centrifugal scarring alopecia (follicular degeneration syndrome). It may be helpful to check a patient for signs of GLS, specifically for discrete follicular papules with no evidence of scarring on the trunk, non-scarring alopecia of the axillary and pubic regions, and well-demarcated retroauricular plaques with prominent follicular papules.

To our knowledge, there are no significant systemic associations with GLS except for psychological ones (22). It may be noteworthy, however, that GLS has been connected with the hepatitis B vaccination and associated with androgen insensitivity syndrome (testicular feminization) (23, 24).

**References**


**AUTHORS’ ADDRESSES**

Barbara Zegarska, MD, PhD, Chair, Department of Cosmetology of Medical University in Bydgoszcz

Danuta Kallas, MD, PhD, Chair, Department of Histology and Embryology at Medical University in Bydgoszcz

Robert A. Schwartz, MD, MPH, Professor & Head of Dermatology, New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103, corresponding author

Rafal Czajkowski, MD, Office of the Chair, Teaching Hospital of Dermatology of Medical University in Bydgoszcz

Grazyna Uchanska, MD, Office of the Chair, same address

Waldemar Placek, MD, PhD, Chair, same address

Acta Dermatoven APA Vol 19, 2010, No 3